Primary prostate cancers with ERG fusions are associated with decreased prostate‐specific membrane antigen expression and uptake on prostate‐specific membrane antigen positron emission tomography imaging

Background Although prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) imaging is increasingly standard for prostate tumor staging at diagnosis, the molecular correlates of PSMA expression are underexplored. Methods Digitally quantified PSMA protein expression was correlated with clinical‐pathologic, immune microenvironment, and molecular features of primary tumors, including those with paired pelvic lymph node metastases. The association of primary tumor ERG fusion status with radiotracer uptake was tested in three clinical trials of initial staging 18 F‐DCFPyL PSMA PET imaging. The association of ERG status with PSMA PET sensitivity for pelvic lymph node metastasis was examined in men undergoing initial PET staging. Results Primary tumor PSMA expression did not vary by self‐identified race or genetic ancestry and was negatively correlated with tumor T‐ and B‐lymphocyte densities. Primary tumors with ERG fusions expressed less PSMA than those without, but this association was not maintained for pelvic lymph node metastases. ERG fusion‐positive primary tumors had lower maximum standardized uptake values compared to ERG fusion‐negative tumors in two of three clinical trials. Among pN1 patients with preoperative imaging, the sensitivity of PSMA PET for nodal metastases was not significantly different by ERG status, although this study was limited by its retrospective and correlative nature. Conclusions PSMA PET primary tumor visualization may be limited by lower expression of PSMA in tumors with ERG fusions, with implications for PET‐based primary tumor staging. However, there is no evidence for decreased PSMA expression—or altered sensitivity of PSMA PET—in lymph node metastases from ERG fusion‐positive tumors.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2026-11-18
DOI
https://doi.org/10.1002/cncr.70675
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Primary prostate cancers with ERG fusions are associated with decreased prostate‐specific membrane antigen expression and uptake on prostate‐specific membrane antigen positron emission tomography imaging

Tamara Levin Lotan, Edward M. Schaeffer, Mohamad Ezzeddine Allaf, Oluwademilade Dairo et al.
1 links
Cancer
Prostate Cancer Diagnosis and Treatment
article

Primary prostate cancers with ERG fusions are associated with decreased prostate‐specific membrane antigen expression and uptake on prostate‐specific membrane antigen positron emission tomography imaging

Tamara Levin Lotan, Edward M. Schaeffer, Mohamad Ezzeddine Allaf, Oluwademilade Dairo, Adam Benjamin Weiner, Ruana Farias Novaes, Martin G. Pomper, Corinne E. Joshu, Andrew F. Voter, Steven P. Rowe, Michael A. Gorin, Hatice Savas, Adrianna Amaral, Patience Pepra-Ameyaw, Morelle Meegane Konchou, Sean Xie, Carolina Gomes-Alexandre, Jiayun Lu, Angelo M. De Marzo, Riya Khandhedia
article en

Abstract

Background Although prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) imaging is increasingly standard for prostate tumor staging at diagnosis, the molecular correlates of PSMA expression are underexplored. Methods Digitally quantified PSMA protein expression was correlated with clinical‐pathologic, immune microenvironment, and molecular features of primary tumors, including those with paired pelvic lymph node metastases. The association of primary tumor ERG fusion status with radiotracer uptake was tested in three clinical trials of initial staging 18 F‐DCFPyL PSMA PET imaging. The association of ERG status with PSMA PET sensitivity for pelvic lymph node metastasis was examined in men undergoing initial PET staging. Results Primary tumor PSMA expression did not vary by self‐identified race or genetic ancestry and was negatively correlated with tumor T‐ and B‐lymphocyte densities. Primary tumors with ERG fusions expressed less PSMA than those without, but this association was not maintained for pelvic lymph node metastases. ERG fusion‐positive primary tumors had lower maximum standardized uptake values compared to ERG fusion‐negative tumors in two of three clinical trials. Among pN1 patients with preoperative imaging, the sensitivity of PSMA PET for nodal metastases was not significantly different by ERG status, although this study was limited by its retrospective and correlative nature. Conclusions PSMA PET primary tumor visualization may be limited by lower expression of PSMA in tumors with ERG fusions, with implications for PET‐based primary tumor staging. However, there is no evidence for decreased PSMA expression—or altered sensitivity of PSMA PET—in lymph node metastases from ERG fusion‐positive tumors.

CancerVol. 132(23)
Northwestern University (US), Cedars-Sinai Medical Center (US), Johns Hopkins University (US), University of California, Los Angeles (US), Johns Hopkins Medicine (US), University of California System (US), The University of Texas Southwestern Medical Center (US), Icahn School of Medicine at Mount Sinai (US)
U.S. Department of Defense, Prostate Cancer Foundation, National Institutes of Health, National Cancer Institute, Congressionally Directed Medical Research Programs, DOD Prostate Cancer Research Program
Good health and well-being
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon